Thin colorectal cancer patients have shorter survival than obese patients
the ONA take:
According to new findings presented today at the ESMO World Congress on Gastrointestinal Cancer in Barcelona, Spain, researchers from Duke University School of Medicine in Durham, North Carolina, have found that thin patients with colorectal cancer have shorter survival than obese patients.
For the study, researchers analyzed data from 6,128 patients who had been treated for untreated metastatic colorectal cancer. All patients received bevacizumab plus chemotherapy.
Researchers found that patients with a body mass index (BMI) between 20 and 24.9 survived a mean of 21.1 after treatment initiation compared with 23.5 months for those with a BMI of 25 to 29 and 24 months for those with a BMI of 30 to 35.
"Contrary to our hypothesis, patients who had the lowest BMI were at risk for having the shortest survival," said lead author Yousuf Zafar, M.D., associate professor of medicine at Duke University. "In this case, patients with the lowest body weight—people who had metastatic colon cancer and a BMI of less than 25—were at the highest risk."
The findings do not mean that being overweight is protective for patients with colorectal cancer undergoing treatment, but rather there could be an underlying mechanism that put thinner patients at an increased risk for poor outcomes.
Thin patients with colorectal cancer have shorter survival than obese patients.
- Novel Blood Test Detects Cancer, Locates Tumor Without Invasive Procedures
- Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer
- Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results
- Colorectal Cancer Rates Increased Sharply Among Generation X and Millennials
- Pneumonia Associated With Common Cold May Cause Fatal Illness in Stem Cell Transplant Recipients
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Ginger Extract Raises Antioxidant Levels in Patients Undergoing Chemotherapy
- Nurse Navigators Improve Physician Engagement in Pretreatment Discussions
- Screening Increases Early Palliative Care, Reduces Aggressive EOL Measures
- Antiperspirants/Deodorants and Breast Cancer (Fact Sheet)
- Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma
- Lifestyle Choices Have Greater Influence on Colon and Rectal Cancer Risk
- Kidney Cancer Metastases in Lung May Hide Undiagnosed Primary Lung Cancer
- Nasal Biomarker in Smokers Could Predict Lung Cancer
- Arm Lymphoscintigraphy After Axillary Lymph Node Dissection or Sentinel Lymph Node Biopsy in Breast Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|